Press Release
Apmonia Therapeutics announces a €2.5 million financing to develop its lead candidate targeting solid cancers
September 2, 2022
9 h 23 min
Apmonia Therapeutics announces a 4 M€ fundraising round to complete regulatory preclinical studies of its anti-cancer immunotherapy drug candidate (AP-01) Success for Apmonia Therapeutics’ technology
Apmonia Therapeutics annonce une nouvelle levée de fonds de 4 M€ lui permettant la finalisation des études précliniques réglementaires de son candidat médicament en immunothérapie
We are pleased to announce our newest paper in Cancers MDPI is now published online! This work unveils the potential of Apmonia Therapeutics’ lead candidate TAX2 (AP-01)
Apmonia Therapeutics’ lead program (AP-01 or TAX2) is a cyclic peptide targeting TSP-1 (a ligand of CD47 receptor) across various tumor indications with high unmet
We are extremely pleased and enthusiastic that we can count upon the valued support of Business Angels Marne-Ardennes (BAMA, former Reims Business Angels)! This enables Apmonia Therapeutics to